PDF(Pubmed)
Abstract：
Patient response after treatment of renal cell cancer (RCC) with systemic agents, which include various drug categories, is generally poor and unpredictable. In this context, the ideal drug administration includes tools to predict the sensitivity of the disease to therapy. The aim of this study was to systematically summarize the reports on the predictive value of the methylation status in the systemic therapy of RCC. Only original articles reporting on the association of promoter methylation with the response of patients or cell lines to systemic agents were included in this review. We applied PRISMA recommendations to the structure and methodology of this systematic review. Our literature search concluded with 31 articles conducted on RCC cell lines and patient tissues. The majority of the studies demonstrated a methylation-dependent response to systemic agents. This correlation suggests that the methylation pattern can be used as a predictive tool in the management of RCC with various classes of systemic agents. However, although methylation biomarkers show promise for predicting response, the evidence of such correlation is still weak. More studies on the gene methylation pattern in patients under systemic therapy and its correlation with different degrees of response are needed.
摘要：
用全身药物治疗肾细胞癌（RCC）后患者的反应，其中包括各种药物类别，通常是贫穷和不可预测的。在这种情况下，理想的药物管理包括预测疾病对治疗的敏感性的工具。本研究旨在系统总结甲基化状态在肾癌全身治疗中的预测价值。本综述仅包括有关启动子甲基化与患者或细胞系对全身性药物的反应相关的原始文章。我们将PRISMA建议应用于本次系统评价的结构和方法。我们的文献检索总结了31篇关于RCC细胞系和患者组织的文章。大多数研究证明了对全身性药物的甲基化依赖性反应。这种相关性表明，甲基化模式可用作各种全身性药物治疗RCC的预测工具。然而,尽管甲基化生物标志物显示出预测反应的前景，这种相关性的证据仍然薄弱。需要更多研究全身治疗患者的基因甲基化模式及其与不同反应程度的相关性。
